Adelaide Research & Scholarship: Search

Search

Search:
for

Current filters:

Start a new search

Add filters:

Results/Page | Sort items by In order Authors/record

Results 11-20 of 26 (Search time: 0.002 seconds).

Item hits:

Preview	Issue Date	Title	Author(s)
	2010	Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity	Engler, J.; Frede, A.; Saunders, V.; Zannettino, A.; Hughes, T.; White, D.
	2010	Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR	Ross, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Bartley, P.; Slader, C.; Field, C.; Dang, P.; Filshie, R.; Mills, A.; Grigg, A.; Vaz de Melo, J.; Hughes, T.
	2010	Practical considerations for monitoring patients with chronic myeloid leukemia	Branford, S.; Hughes, T.
	2010	Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors	Hiwase, D.; White, D.; Powell, J.; Saunders, V.; Zrim, S.; Frede, A.; Guthridge, M.; Lopez, A.; D'Andrea, R.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.
	2010	Nilotinib versus Imatinib for newly diagnosed chronic myeloid leukemia	Saglio, G.; Kim, D.; Issaragrisil, S.; le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R.; Hochhaus, A.; Hughes, T.; Gallagher, N.; Hoenekopp, A.; Haque, A.; Dong, M.; Larson, R.; Kantarjian, H.
	2010	Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA	Bartley, P.; Ross, D.; Latham, S.; Martin-Harris, M.; Budgen, B.; Wilczek, V.; Branford, S.; Hughes, T.; Morley, A.
	2010	Primary tooth emergence in Australian children: timing, sequence and patterns of asymmetry	Woodroffe, S.; Mihailidis, S.; Hughes, T.; Bockmann, M.; Seow, W.; Gotjamanos, T.; Townsend, G.
	2010	Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)	Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
	2010	Dysregulation of bone remodeling by imatinib mesylate	Vandyke, K.; Fitter, S.; Dewar, A.; Hughes, T.; Zannettino, A.
	2010	The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cells	Engler, J.; Frede, A.; Saunders, V.; Zannettino, A.; White, D.; Hughes, T.